Treatment options for nonresponders and relapsers to initial therapy for hepatitis C

Cleveland Clinic Journal of Medicine

Volumn 70, Issue SUPPL. 4, 2003, Pages

  Duncan, Marten ^a,b   Younossi, Zobair ^a  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; PEGINTERFERON; RIBAVIRIN; VIRUS RNA; ANTIVIRUS AGENT; INTERFERON;

DISEASE COURSE; DRUG EFFECT; GENOTYPE; HEPATITIS C; HUMAN; MONOTHERAPY; RELAPSE; REVIEW; RISK FACTOR; TREATMENT OUTCOME; TREATMENT PLANNING; ANTIBIOTIC RESISTANCE; DRUG COMBINATION; GENETICS; HEPATITIS C VIRUS; LIVER CELL CARCINOMA; LIVER TUMOR; RECURRENT DISEASE; RETREATMENT;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER NEOPLASMS; RECURRENCE; RETREATMENT; RIBAVIRIN;

EID: 0642375762     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.70.suppl_4.s21     Document Type: Review

References (41)

1. McHutchinson JG, Gordon S, Shiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339:1485-1492.
2. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352:1426-1432.
3. National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C: 2002. Available at: http://consensus.nih.gov/cons/ 116/Hepc091202.pdf.
4. Lindsay KL. Therapy of hepatitis C: overview. From the National Institutes of Health Consensus Development Conference: Management of Hepatitis C. Hepatology 1997; 26(suppl 1):71S-77S.
5. Pawlotsky JM, Germanidis G, Neumann AU, et al. Interferon resistance of hepatitis C virus genotype 1b: relationship to non-structural 5A quasispecies mutations. J Virol 1998; 72:2795-2805.
6. Polyak SJ, McArdle S, Liu SL, et al. Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection. J Virol 1998; 72:4288-4296.
7. Roffi L, Mels GC, Antonelli G, et al. Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management. Hepatology 1995; 21:645-649.
8. Shiffman ML. Management of interferon therapy nonresponders. Clin Liver Dis 2001; 5:1025-1043.
9. Heathcote EJ, James S, Mullen KD, et al. Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon. The Consensus Interferon Study Group. Hepatology 1999; 30:562-566.
10. Van Thiel DH, Kondaveeti K, Friedlander L. Retreatment of high-dose interferon (5 MU daily) nonresponders with high-dose IFN + ribavirin. Dig Dis Sci 2002; 47:1932-1935.
11. Fontana RJ, Walsh J, Moyer CA, et al. High-dose interferon alfa-2b and ribavirin in patients previously treated with interferon: results of a prospective randomized, controlled trial. J Clin Gastroenterol 2002; 34:177-182.
12. DiBisceglie AM, Thompson J, Smith-Wilkaitis N, et al. Combination of interferon in chronic hepatitis C: retreatment of nonresponders to interferon. Hepatology 2001; 33:704-707.
13. Shiffman ML, Hofmann CM, Gabbay J, et al. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. Am J Gastroenterol 2000; 95:2928-2935.
14. Cheng SJ, Bonis PA, Lau J, et al. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials. Hepatology 2001; 33:231-240.
15. Fried MW, Schiffman ML, Reddy KR, et al. Pegylated (40 kDa) interferon-alfa-2a (PEGASYS) in combination with ribavirin: efficacy and safety results from a phase III, randomized actively-controlled, multicenter study [abstract]. Gastroenterology 2001; 120(suppl 1): A55.
16. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
17. Shiffman ML, HALT-C Trial Investigators. Retreatment of HCV non-responders with peginterferon and ribavirin: results from the lead-in phase of the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis (HALT-C) trial [abstract]. Hepatology 2002; 36(4 Pt 2):295A. Abstract 527.
18. Jacobson IM, Russo MW, Brown RS Jr, et al. Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: a trial in prior nonresponders to interferon monotherapy or combination therapy and in combination therapy relapsers [abstract]. Gastroenterology 2002; 122(suppl):A626. Abstract 79.
19. Lawitz EJ, Cantu NS, Becker S, et al. Pegylated interferon alfa 2b (PEG-IFN) and ribavirin for hepatitis C patients who were nonresponders to previous therapy [abstract]. Gastroenterology 2002; 122(suppl):A626. Abstract 80.
20. Younossi ZM, McCullough AJ, Barnes DS, et al. Pegylated interferon, ribavirin and amantadine for treatment of chronic hepatitis C: a multicenter clinical trial [abstract]. Hepatology 2002; 36(4 Pt 2):603A. Abstract 1760.
21. Khalili M, Denham C, Perrillo R. Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C. Am J Gastroenterol 2000; 95:1284-1289.
22. Younossi ZM, Mullen KD, Zakko W, et al. A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. Interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responders to interferon monotherapy. J Hepatol 2001; 34:128-133.
23. Brillanti S, Levantesi F, Masi L, Foli M, Bolondi L. Triple antiviral therapy as a new option for patients with interferon non-responsive chronic hepatitis C. Hepatology 2000; 32:630-634.
24. Younossi ZM, Mullen KD, Hodnick S, et al. Triple combination of interferon alpha-2b, ribavirin, and amantadine for treatment of chronic hepatitis C. J Clin Gastroenterol 2003; 36:427-430.
25. Shiffman ML. Histology improvement in response to interferon therapy in chronic hepatitis C. Viral Hepatitis Rev 1999; 5:27-43.
26. Shiffman ML, Hofmann CM, Contos MJ, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999; 117:1164-1172.
27. Angelico M, Gandin C, Pescarmona E, et al. Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up. Am J Gastroenterol 1995; 90:263-269.
28. Boucher E, Jouanolle H, Andre P, et al. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients. Hepatology 1995; 21:322-327.
29. Takano S, Ito Y, Yokosuka O, et al. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 1994; 20:558-564.
30. Angelico M, Cepparulo M, Barlattani A, et al. Unfavourable effects of colchicine in combination with interferon-alpha in the treatment of chronic hepatitis C. Aliment Pharmacol Ther 2000; 14:1459-1467.
31. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340:745-750.
32. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998; 75:347-354.
33. Tobe T, Arii S. Improving survival after resection of hepatocellular carcinoma: characteristics and current status of surgical treatment of primary liver cancer in Japan. In: Tobe T, Kaneda H, Okudaira M, et al, eds. Primary Liver Cancer in Japan. Tokyo: Springer; 1992:219-221.
34. Bruno S, Silini E, Crosignani A, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1997; 25:754-758.
35. Yuen M, Cheng C, Lauder IJ, et al. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000; 31:330-335.
36. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy-reduces the risk for hepatocellular carcinoma. Ann Intern Med 1999; 131:174-181.
37. Imai Y, Kawata S, Tamura S, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med 1998; 129:94-99.
38. Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study on 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29:1124-1130.
39. Nishiguchi S, Shiomi S, Nakatani S, et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001; 357:196-197.
40. Shindo M, Hamada K, Oda Y, Okuno T. Long-term follow-up of the sustained biochemical responders with interferon therapy. Hepatology 2001; 33:1299-1302.
41. Kubo S, Nishiguchi S, Hirohashi K, et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. Ann Intern Med 2001; 134:963-967.